Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes

Robert Higgins, Maureen McKisic, Peter J Dickinson, Daniel F. Jimenez, Steven W. Dow, Linda D. Tripp, Richard A Lecouteur

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The effect of a cationic liposome non-coding plasmid DNA complex on the growth of an intracerebral glioblastoma in an immunocompetent syngeneic mouse strain was evaluated. Previous studies of extraneural tumors in mice have demonstrated that such complexes containing plasmid DNA are capable of stimulating a potent Th-1 cytokine immune-mediated response with a dramatic inhibition of tumor growth. A DOTIM-cholesterol cationic liposome complexed to non-coding plasmid DNA (EV-CLDC) was administered intravenously (i.v.) at weekly intervals to 6-week-old male mice of the B6D2F1 strain at either 3, 10 or 17 days post-inoculation (DPI) of 4C8 glioblastoma cells. Tumor growth was monitored by volumetric image analysis obtained from sequential weekly magnetic resonance imaging studies of the brain. Experiments were terminated between 30 to 38 DPI. Terminal tumor volumes calculated from histological sections directly correlated with tumor volumes from corresponding MR images. The EV-CLDC administered at 3 DPI resulted in a statistically significant (P < 0.0001) sustained inhibition of tumor growth compared with tumors in mice administered only individual components of the EV-CLDC. The EV-CLDC similarly inhibited growth of longer established glioblastomas. Histopathologic evaluation of terminal tumors did not find any hemorrhage, edema or necrosis in either the EV-CLDC-treated or control tumors. The results indicate that an i.v.-administered EV-CLDC can significantly inhibit the growth of a brain tumor in immunocompetent syngeneic mice.

Original languageEnglish (US)
Pages (from-to)338-344
Number of pages7
JournalCancer Immunology, Immunotherapy
Volume53
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Glioblastoma
Lipids
DNA
Growth
Neoplasms
Plasmids
Tumor Burden
Liposomes
Brain Neoplasms
Edema
Necrosis
Cholesterol
Magnetic Resonance Imaging
Hemorrhage
Cytokines
Brain

Keywords

  • 4C8 cells
  • B6D2F1 strain
  • Brain tumor
  • Cationic liposome-DNA complex
  • EV-CLDC
  • Glioblastoma
  • Mice
  • MR imaging

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes. / Higgins, Robert; McKisic, Maureen; Dickinson, Peter J; Jimenez, Daniel F.; Dow, Steven W.; Tripp, Linda D.; Lecouteur, Richard A.

In: Cancer Immunology, Immunotherapy, Vol. 53, No. 4, 04.2004, p. 338-344.

Research output: Contribution to journalArticle

@article{0653c43782dc4f97a53e70e77afd3942,
title = "Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes",
abstract = "The effect of a cationic liposome non-coding plasmid DNA complex on the growth of an intracerebral glioblastoma in an immunocompetent syngeneic mouse strain was evaluated. Previous studies of extraneural tumors in mice have demonstrated that such complexes containing plasmid DNA are capable of stimulating a potent Th-1 cytokine immune-mediated response with a dramatic inhibition of tumor growth. A DOTIM-cholesterol cationic liposome complexed to non-coding plasmid DNA (EV-CLDC) was administered intravenously (i.v.) at weekly intervals to 6-week-old male mice of the B6D2F1 strain at either 3, 10 or 17 days post-inoculation (DPI) of 4C8 glioblastoma cells. Tumor growth was monitored by volumetric image analysis obtained from sequential weekly magnetic resonance imaging studies of the brain. Experiments were terminated between 30 to 38 DPI. Terminal tumor volumes calculated from histological sections directly correlated with tumor volumes from corresponding MR images. The EV-CLDC administered at 3 DPI resulted in a statistically significant (P < 0.0001) sustained inhibition of tumor growth compared with tumors in mice administered only individual components of the EV-CLDC. The EV-CLDC similarly inhibited growth of longer established glioblastomas. Histopathologic evaluation of terminal tumors did not find any hemorrhage, edema or necrosis in either the EV-CLDC-treated or control tumors. The results indicate that an i.v.-administered EV-CLDC can significantly inhibit the growth of a brain tumor in immunocompetent syngeneic mice.",
keywords = "4C8 cells, B6D2F1 strain, Brain tumor, Cationic liposome-DNA complex, EV-CLDC, Glioblastoma, Mice, MR imaging",
author = "Robert Higgins and Maureen McKisic and Dickinson, {Peter J} and Jimenez, {Daniel F.} and Dow, {Steven W.} and Tripp, {Linda D.} and Lecouteur, {Richard A}",
year = "2004",
month = "4",
doi = "10.1007/s00262-003-0447-y",
language = "English (US)",
volume = "53",
pages = "338--344",
journal = "Cancer Immunology, Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

TY - JOUR

T1 - Growth inhibition of an orthotopic glioblastoma in immunocompetent mice by cationic lipid-DNA complexes

AU - Higgins, Robert

AU - McKisic, Maureen

AU - Dickinson, Peter J

AU - Jimenez, Daniel F.

AU - Dow, Steven W.

AU - Tripp, Linda D.

AU - Lecouteur, Richard A

PY - 2004/4

Y1 - 2004/4

N2 - The effect of a cationic liposome non-coding plasmid DNA complex on the growth of an intracerebral glioblastoma in an immunocompetent syngeneic mouse strain was evaluated. Previous studies of extraneural tumors in mice have demonstrated that such complexes containing plasmid DNA are capable of stimulating a potent Th-1 cytokine immune-mediated response with a dramatic inhibition of tumor growth. A DOTIM-cholesterol cationic liposome complexed to non-coding plasmid DNA (EV-CLDC) was administered intravenously (i.v.) at weekly intervals to 6-week-old male mice of the B6D2F1 strain at either 3, 10 or 17 days post-inoculation (DPI) of 4C8 glioblastoma cells. Tumor growth was monitored by volumetric image analysis obtained from sequential weekly magnetic resonance imaging studies of the brain. Experiments were terminated between 30 to 38 DPI. Terminal tumor volumes calculated from histological sections directly correlated with tumor volumes from corresponding MR images. The EV-CLDC administered at 3 DPI resulted in a statistically significant (P < 0.0001) sustained inhibition of tumor growth compared with tumors in mice administered only individual components of the EV-CLDC. The EV-CLDC similarly inhibited growth of longer established glioblastomas. Histopathologic evaluation of terminal tumors did not find any hemorrhage, edema or necrosis in either the EV-CLDC-treated or control tumors. The results indicate that an i.v.-administered EV-CLDC can significantly inhibit the growth of a brain tumor in immunocompetent syngeneic mice.

AB - The effect of a cationic liposome non-coding plasmid DNA complex on the growth of an intracerebral glioblastoma in an immunocompetent syngeneic mouse strain was evaluated. Previous studies of extraneural tumors in mice have demonstrated that such complexes containing plasmid DNA are capable of stimulating a potent Th-1 cytokine immune-mediated response with a dramatic inhibition of tumor growth. A DOTIM-cholesterol cationic liposome complexed to non-coding plasmid DNA (EV-CLDC) was administered intravenously (i.v.) at weekly intervals to 6-week-old male mice of the B6D2F1 strain at either 3, 10 or 17 days post-inoculation (DPI) of 4C8 glioblastoma cells. Tumor growth was monitored by volumetric image analysis obtained from sequential weekly magnetic resonance imaging studies of the brain. Experiments were terminated between 30 to 38 DPI. Terminal tumor volumes calculated from histological sections directly correlated with tumor volumes from corresponding MR images. The EV-CLDC administered at 3 DPI resulted in a statistically significant (P < 0.0001) sustained inhibition of tumor growth compared with tumors in mice administered only individual components of the EV-CLDC. The EV-CLDC similarly inhibited growth of longer established glioblastomas. Histopathologic evaluation of terminal tumors did not find any hemorrhage, edema or necrosis in either the EV-CLDC-treated or control tumors. The results indicate that an i.v.-administered EV-CLDC can significantly inhibit the growth of a brain tumor in immunocompetent syngeneic mice.

KW - 4C8 cells

KW - B6D2F1 strain

KW - Brain tumor

KW - Cationic liposome-DNA complex

KW - EV-CLDC

KW - Glioblastoma

KW - Mice

KW - MR imaging

UR - http://www.scopus.com/inward/record.url?scp=1642325436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642325436&partnerID=8YFLogxK

U2 - 10.1007/s00262-003-0447-y

DO - 10.1007/s00262-003-0447-y

M3 - Article

C2 - 14618278

AN - SCOPUS:1642325436

VL - 53

SP - 338

EP - 344

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

SN - 0340-7004

IS - 4

ER -